KRAS, BRAF and PIK3CA status in squamous cell anal carcinoma (SCAC)

Andrea Casadei Gardini, Laura Capelli, Paola Ulivi, Massimo Giannini, Eva Freier, Stefano Tamberi, Emanuela Scarpi, Alassandro Passardi, Wainer Zoli, Angela Ragazzini, Dino Amadori, Giovanni Luca Frassinet

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Anti-EGFR therapy appears to be a potential treatment option for squamous cell anal carcinoma (SCAC). KRAS mutation is a rare event in SCAC, indicating the absence of the principal mechanism of resistance to this type of therapy. However, no information is available from the literature regarding the status of BRAF or PIK3CA in this cancer type. We analysed KRAS, BRAF and PIK3CA status in SCAC patients in relation to the clinical-pathological characteristics of patients and to the presence of the human papilloma virus (HPV). One hundred and three patients were treated with the Nigro scheme for anal cancer from March 2001 to August 2012. Fifty patients were considered for the study as there was insufficient paraffinembedded tumour tissue to perform molecular analysis the remaining 53. DNA was extracted from paraffin-embedded sections. KRAS, BRAF and PIK3CA gene status and HPV genotype were evaluated by pyrosequencing. KRAS and BRAF genes were wild-type in all cases. Conversely, PIK3CA gene was found to be mutated in 11 (22%) cases. In particular, 8 mutations occurred in exon 9 and 3 in exon 20 of the PIK3CA gene. These findings suggest that SCAC could potentially respond to an anti-EGFR drug. PIK3CA mutation may be involved in the process of carcinogenesis in some cases of SCAC.

Original languageEnglish
Article numbere92071
JournalPLoS One
Volume9
Issue number3
DOIs
Publication statusPublished - Mar 18 2014

Fingerprint

carcinoma
Squamous Cell Carcinoma
Papillomaviridae
Genes
papilloma
mutation
Viruses
Mutation
neoplasms
exons
cells
Exons
genes
Anus Neoplasms
viruses
therapeutics
resistance mechanisms
Paraffin
alkanes
carcinogenesis

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

KRAS, BRAF and PIK3CA status in squamous cell anal carcinoma (SCAC). / Gardini, Andrea Casadei; Capelli, Laura; Ulivi, Paola; Giannini, Massimo; Freier, Eva; Tamberi, Stefano; Scarpi, Emanuela; Passardi, Alassandro; Zoli, Wainer; Ragazzini, Angela; Amadori, Dino; Frassinet, Giovanni Luca.

In: PLoS One, Vol. 9, No. 3, e92071, 18.03.2014.

Research output: Contribution to journalArticle

@article{f49ecf281f9c47a8b2135e101c4fd61d,
title = "KRAS, BRAF and PIK3CA status in squamous cell anal carcinoma (SCAC)",
abstract = "Anti-EGFR therapy appears to be a potential treatment option for squamous cell anal carcinoma (SCAC). KRAS mutation is a rare event in SCAC, indicating the absence of the principal mechanism of resistance to this type of therapy. However, no information is available from the literature regarding the status of BRAF or PIK3CA in this cancer type. We analysed KRAS, BRAF and PIK3CA status in SCAC patients in relation to the clinical-pathological characteristics of patients and to the presence of the human papilloma virus (HPV). One hundred and three patients were treated with the Nigro scheme for anal cancer from March 2001 to August 2012. Fifty patients were considered for the study as there was insufficient paraffinembedded tumour tissue to perform molecular analysis the remaining 53. DNA was extracted from paraffin-embedded sections. KRAS, BRAF and PIK3CA gene status and HPV genotype were evaluated by pyrosequencing. KRAS and BRAF genes were wild-type in all cases. Conversely, PIK3CA gene was found to be mutated in 11 (22{\%}) cases. In particular, 8 mutations occurred in exon 9 and 3 in exon 20 of the PIK3CA gene. These findings suggest that SCAC could potentially respond to an anti-EGFR drug. PIK3CA mutation may be involved in the process of carcinogenesis in some cases of SCAC.",
author = "Gardini, {Andrea Casadei} and Laura Capelli and Paola Ulivi and Massimo Giannini and Eva Freier and Stefano Tamberi and Emanuela Scarpi and Alassandro Passardi and Wainer Zoli and Angela Ragazzini and Dino Amadori and Frassinet, {Giovanni Luca}",
year = "2014",
month = "3",
day = "18",
doi = "10.1371/journal.pone.0092071",
language = "English",
volume = "9",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "3",

}

TY - JOUR

T1 - KRAS, BRAF and PIK3CA status in squamous cell anal carcinoma (SCAC)

AU - Gardini, Andrea Casadei

AU - Capelli, Laura

AU - Ulivi, Paola

AU - Giannini, Massimo

AU - Freier, Eva

AU - Tamberi, Stefano

AU - Scarpi, Emanuela

AU - Passardi, Alassandro

AU - Zoli, Wainer

AU - Ragazzini, Angela

AU - Amadori, Dino

AU - Frassinet, Giovanni Luca

PY - 2014/3/18

Y1 - 2014/3/18

N2 - Anti-EGFR therapy appears to be a potential treatment option for squamous cell anal carcinoma (SCAC). KRAS mutation is a rare event in SCAC, indicating the absence of the principal mechanism of resistance to this type of therapy. However, no information is available from the literature regarding the status of BRAF or PIK3CA in this cancer type. We analysed KRAS, BRAF and PIK3CA status in SCAC patients in relation to the clinical-pathological characteristics of patients and to the presence of the human papilloma virus (HPV). One hundred and three patients were treated with the Nigro scheme for anal cancer from March 2001 to August 2012. Fifty patients were considered for the study as there was insufficient paraffinembedded tumour tissue to perform molecular analysis the remaining 53. DNA was extracted from paraffin-embedded sections. KRAS, BRAF and PIK3CA gene status and HPV genotype were evaluated by pyrosequencing. KRAS and BRAF genes were wild-type in all cases. Conversely, PIK3CA gene was found to be mutated in 11 (22%) cases. In particular, 8 mutations occurred in exon 9 and 3 in exon 20 of the PIK3CA gene. These findings suggest that SCAC could potentially respond to an anti-EGFR drug. PIK3CA mutation may be involved in the process of carcinogenesis in some cases of SCAC.

AB - Anti-EGFR therapy appears to be a potential treatment option for squamous cell anal carcinoma (SCAC). KRAS mutation is a rare event in SCAC, indicating the absence of the principal mechanism of resistance to this type of therapy. However, no information is available from the literature regarding the status of BRAF or PIK3CA in this cancer type. We analysed KRAS, BRAF and PIK3CA status in SCAC patients in relation to the clinical-pathological characteristics of patients and to the presence of the human papilloma virus (HPV). One hundred and three patients were treated with the Nigro scheme for anal cancer from March 2001 to August 2012. Fifty patients were considered for the study as there was insufficient paraffinembedded tumour tissue to perform molecular analysis the remaining 53. DNA was extracted from paraffin-embedded sections. KRAS, BRAF and PIK3CA gene status and HPV genotype were evaluated by pyrosequencing. KRAS and BRAF genes were wild-type in all cases. Conversely, PIK3CA gene was found to be mutated in 11 (22%) cases. In particular, 8 mutations occurred in exon 9 and 3 in exon 20 of the PIK3CA gene. These findings suggest that SCAC could potentially respond to an anti-EGFR drug. PIK3CA mutation may be involved in the process of carcinogenesis in some cases of SCAC.

UR - http://www.scopus.com/inward/record.url?scp=84898670648&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84898670648&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0092071

DO - 10.1371/journal.pone.0092071

M3 - Article

VL - 9

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 3

M1 - e92071

ER -